Robert Cavorsi
Corporate Officer/Principal bei ORGANOGENESIS HOLDINGS INC.
Vermögen: 131 237 $ am 30.04.2024
Profil
Robert Cavorsi is currently the Vice President-Strategy at Organogenesis Holdings, Inc. He previously worked as the Neurology Director-Sales Operations at Sumitomo Pharma America, Inc. from 2015 to 2016.
He obtained his undergraduate degree from The Pennsylvania State University.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 19.04.2024 | 57 434 ( 0,04% ) | 131 237 $ | 30.04.2024 |
Aktive Positionen von Robert Cavorsi
| Unternehmen | Position | Beginn |
|---|---|---|
| ORGANOGENESIS HOLDINGS INC. | Corporate Officer/Principal | 01.01.2021 |
Ehemalige bekannte Positionen von Robert Cavorsi
| Unternehmen | Position | Ende |
|---|---|---|
Sumitomo Pharma America, Inc.
 Sumitomo Pharma America, Inc. Pharmaceuticals: MajorHealth Technology Sumitomo Pharma America, Inc. operates as a biopharmaceutical company that develops pharmaceutical products. Its products include Aptiom (eslicarbazepine acetate) tablets, Latuda (lurasidone HCl) tablets, Lunesta (eszopiclone) tablets, Xopenex (levalbuterol HCl) Inhalation Solution, Xopenex HFA (levalbuterol tartrate) Inhalation Aerosol, Brovana (arformoterol tartrate) Inhalation Solution, Omnaris (ciclesonide) Nasal Spray, Alvesco (ciclesonide) Inhalation Aerosol, and Zetonna (ciclesonide) Nasal Aerosol. The company was founded in 2010 and is headquartered in Marlborough, MA. | Vertrieb & Marketing | 01.01.2016 |
Ausbildung von Robert Cavorsi
| The Pennsylvania State University | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| ORGANOGENESIS HOLDINGS INC. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Sumitomo Pharma America, Inc.
Sumitomo Pharma America, Inc. Pharmaceuticals: MajorHealth Technology Sumitomo Pharma America, Inc. operates as a biopharmaceutical company that develops pharmaceutical products. Its products include Aptiom (eslicarbazepine acetate) tablets, Latuda (lurasidone HCl) tablets, Lunesta (eszopiclone) tablets, Xopenex (levalbuterol HCl) Inhalation Solution, Xopenex HFA (levalbuterol tartrate) Inhalation Aerosol, Brovana (arformoterol tartrate) Inhalation Solution, Omnaris (ciclesonide) Nasal Spray, Alvesco (ciclesonide) Inhalation Aerosol, and Zetonna (ciclesonide) Nasal Aerosol. The company was founded in 2010 and is headquartered in Marlborough, MA. | Health Technology |
